Trial
NCT00973141
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
—
Condition
Osteoarthritis
Intervention
JNJ-42160443
Why stopped
Logistic reasons associated with the FDA-imposed clinical hold.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-11